美国癌症研究协会-第101届年会-研究新的治疗候选药物:第二部分。

Idrugs Pub Date : 2010-06-01

Vicki L Mason

{"title":"美国癌症研究协会-第101届年会-研究新的治疗候选药物:第二部分。","authors":"Vicki L Mason","doi":"","DOIUrl":null,"url":null,"abstract":"The 101st Annual Meeting of the American Association of Cancer Research, held in Washington, DC, included topics covering new therapeutic developments in the field of cancer research. This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB) to block tumor growth in vivo. Phase I clinical trial results for VB-111 (VBL Therapeutics) are also presented.","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 6","pages":"360-2"},"PeriodicalIF":0.0000,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2.\",\"authors\":\"Vicki L Mason\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The 101st Annual Meeting of the American Association of Cancer Research, held in Washington, DC, included topics covering new therapeutic developments in the field of cancer research. This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB) to block tumor growth in vivo. Phase I clinical trial results for VB-111 (VBL Therapeutics) are also presented.\",\"PeriodicalId\":55031,\"journal\":{\"name\":\"Idrugs\",\"volume\":\"13 6\",\"pages\":\"360-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Idrugs\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Idrugs","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

第101届美国癌症研究协会年会在华盛顿特区举行，会议的主题涵盖了癌症研究领域的新治疗进展。本次会议报告重点介绍了新型泛PI3K嘧啶衍生抑制剂BKM-120(诺华公司)的临床前数据，PF-4691502(辉瑞公司)对NSCLC中mTOR/PI3K的双重抑制，小分子PDK-1抑制剂PF-05177624和PF-05197281(辉瑞公司)以及RO-5323441 (F hoffmanla Roche Ltd/ThromboGenics NV/BioInvent International AB)在体内阻断肿瘤生长的能力。VB-111 (VBL Therapeutics)的I期临床试验结果也被公布。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

American association for cancer research - 101st annual meeting - investigating new therapeutic candidates: part 2.

The 101st Annual Meeting of the American Association of Cancer Research, held in Washington, DC, included topics covering new therapeutic developments in the field of cancer research. This conference report highlights selected presentations on preclinical data on the novel pan-PI3K pyrimidine-derived inhibitor BKM-120 (Novartis AG), the dual inhibition of mTOR/PI3K in NSCLC by PF-4691502 (Pfizer Inc), the small-molecule PDK-1 inhibitors PF-05177624 and PF-05197281 (both Pfizer) and the ability of RO-5323441 (F Hoffmann-La Roche Ltd/ThromboGenics NV/BioInvent International AB) to block tumor growth in vivo. Phase I clinical trial results for VB-111 (VBL Therapeutics) are also presented.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Idrugs 医学-药学

自引率

0.00%

发文量

审稿时长

>12 weeks